Jubilant Pharmova (530019) Q4 24/25 earnings summary

Executive summary

• FY25 revenue grew 8% year-over-year to Rs. 7,235 Cr (₹72,345 million), driven by growth in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, and CRDMO segments.

• EBITDA margin expanded to 16.9% in FY25 from 14.7% in FY24, with Normalised PAT up 112% year-over-year to Rs. 415 Cr.

• Net profit for FY25 was ₹8,363 million, a significant increase from ₹727 million in FY24.

• Vision 2030 targets doubling revenue from FY24 levels, EBITDA margin of 23–25%, zero net debt, and high-teens ROCE.

• The Board recommended a dividend of ₹5 per equity share, totaling ₹796 million, subject to AGM approval.

Financial highlights

• Q4'FY25 revenue rose 10% year-over-year to Rs. 1,929 Cr; EBITDA up 23% to Rs. 357 Cr; Normalised PAT up 127% to Rs. 139 Cr.

• EBITDA and operating profit improved, with profit before tax at ₹9,806 million for FY25, compared to ₹1,705 million in FY24.

• Earnings per share (EPS) for FY25 was ₹52.99 (basic), up from ₹4.87 in FY24.

• Net debt reduced to Rs. 1,299 Cr as of March 2025, with Net Debt/EBITDA improving to 1.1x.

• USD 125 million voluntary prepayment and SOFIE Biosciences stake sale proceeds used to reduce debt.

Outlook and guidance

• Revenue expected to double by FY30, with EBITDA margin targeted at 23–25% and net debt to reach zero.

• Segmental growth driven by new product launches, capacity expansions, and increased focus on high-margin businesses.

• Roorkee facility's USFDA status upgraded to "VAI" in April 2024, reopening US supplies.

• Continued focus on quality improvements and cGMP compliance at manufacturing sites.